NOTE: There are a lot on my watchlist today which did not yet run. Please do include them in your watchlist up to next week because there are delayed market reactions to news overshadowed by runners. $Chimerix (CMRX.US)$PR 12/9 after hours To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End. Ran 100%+ but this is after hour news with conference call tomorrow at 8:30AM ET. May co...
Jaguar8
OP
michael_11
:
Yes mostly because it increases EPS, less dilution risk, and gives more value to shareholders and attractive to investors. Drawback is it has higher volatility and lesser liquidity
$Chimerix (CMRX.US)$Chimerix To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End Benzinga· 1 min ago Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET
$Chimerix (CMRX.US)$ Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End Monday, 9th December at 4:01 pm Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET
$Chimerix (CMRX.US)$ PR 12/9 after hours To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End. Ran 100%+ but this is after hour news with conference call tomorrow at 8:30AM ET. May co...
On Watch for tomorrow, likely will be a target for shorts though, we'll see.
📊⚡️📊
Benzinga· 1 min ago
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma
Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA
Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
Monday, 9th December at 4:01 pm
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma
Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA
Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET
No comment yet